Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 4
1(33.3%)
N/A
1(33.3%)
Phase 3
1(33.3%)
3Total
Phase 4(1)
N/A(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02860442Not ApplicableCompleted

Project Guard: Reducing Alcohol Misuse/Abuse in the National Guard

Role: lead

NCT02909504Phase 4Terminated

Gao NARASD Lithium Study

Role: lead

NCT00868374Phase 3Terminated

Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder

Role: lead

All 3 trials loaded